BeOne Medicines (ONC) Proxy filing summary

Executive summary

• Achieved GAAP profitability and strong cash flow in 2025, with 40% revenue growth to $5.3B and net income of $287M, marking a turnaround from prior losses.

• Completed redomiciliation to Switzerland and rebranded, reflecting a global footprint and commitment to oncology innovation.

• Expanded patient reach, with over two million patients treated and a workforce of nearly 12,000 across six continents.

• Advanced a robust pipeline in hematology and solid tumors, with multiple late-stage programs and regulatory milestones anticipated in 2026.

• Maintained a strong balance sheet, supporting continued R&D, business development, and global expansion.

Voting matters and shareholder proposals

• 20 proposals include approval of financial statements, discharge of directors, election/re-election of directors and committee members, auditor appointments, executive compensation, amendments to equity plans, share issuance and repurchase mandates, and authorization for Amgen to maintain its shareholding.

• Board recommends voting FOR all proposals and director nominees.

• Shareholders can vote in person, by proxy, or electronically, with detailed instructions for various share classes and geographies.

Board of directors and corporate governance

• Board to be reduced to 10 members, with a majority of independent directors and three female directors, meeting Swiss gender diversity requirements.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, Scientific Advisory, and Commercial and Medical Affairs.

• Lead Independent Director role established for enhanced governance.

• Annual board and committee evaluations, with a focus on diversity, expertise, and global experience.